Amgen announces $13.4bn acquisition of Celgene psoriasis treatment
27-08-2019
Sundry Photography / Shutterstock.com
Amgen is unlikely to succeed in its bid to revive its patents for the cholesterol drug Repatha, a judge at the US Court of Appeals for the Federal Circuit has told the pharmaceutical company.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Amgen, cholesterol, patents, Federal Circuit, Repatha, US District Court for the District of Delaware, big pharma, Sanofi, Regeneron, anitbodies, invention
